[Latest] Global Carbonated Beverages Market Size/Share Worth USD 771.3 Billion by 2033 at a 5.60% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
17 mai 2024 03h30 HE
|
Custom Market Insights
Austin, TX, USA, May 17, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Carbonated Beverages Market Size, Trends and Insights By Product Type (Cola...
Post-consumer Recycled Plastics Market Analysis Report 2024, By Source (Bottles, Non-bottle Rigid), By Type (PP, PS, PE, PVC, PET) and Region
16 mai 2024 10h40 HE
|
Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Post-consumer Recycled Plastics Market Size, Share & Trends Analysis Report By Source (Bottles, Non-bottle Rigid), By Type (PP, PS, PE, PVC, PET),...
[Latest] Global Sports and Energy Drinks Market Size/Share Worth USD 150.22 Billion by 2033 at a 7.48% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
14 mai 2024 05h30 HE
|
Custom Market Insights
Austin, TX, USA, May 14, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Sports and Energy Drinks Market Size, Trends and Insights By Product Type (Sports...
Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab
25 avr. 2024 10h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
23 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 23, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Study Results from Intranasal Anti-CD3 Foralumab in Multiple Sclerosis Patients with PIRA Highlighted in Neurology Today®
19 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
- Intranasal foralumab attenuated microglial activation in patients with non-active secondary progressive multiple sclerosis and progression independent of relapse (PIRA) -- Data presented in a...
Tiziana Life Sciences Announces New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
18 avr. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
CARBIOS公司在2024年香港國際創科展（InnoEX）之際榮獲“非常法國、非凡創新”（So French So Innovative）獎，該獎項旨在表彰法國在亞太地區的卓越創新貢獻
16 avr. 2024 12h30 HE
|
Carbios
CARBIOS公司在2024年香港國際創科展（InnoEX）之際榮獲“非常法國、非凡創新”（So French So Innovative）獎，該獎項旨在表彰法國在亞太地區的卓越創新貢獻 ...
CARBIOS公司在2024年香港国际创科展（InnoEX）之际荣获“非常法国、非凡创新”（So French So Innovative）奖，该奖项旨在表彰法国在亚太地区的卓越创新贡献
16 avr. 2024 12h30 HE
|
Carbios
CARBIOS公司在2024年香港国际创科展（InnoEX）之际荣获“非常法国、非凡创新”（So French So Innovative）奖，该奖项旨在表彰法国在亚太地区的卓越创新贡献 ...
CARBIOS wins "So French So Innovative" award at InnoEX 2024, Hong Kong, recognizing French innovation in Asia Pacific
16 avr. 2024 12h30 HE
|
Carbios
CARBIOS wins "So French So Innovative" award at InnoEX 2024, Hong Kong, recognizing French innovation in Asia Pacific Clermont-Ferrand, France, Tuesday 16 April 2024 (6.30pm CET) CARBIOS...